Intercept Pharmaceuticals Inc ICPT shares are trading higher by $5 at $146.77 in Tuesday's session. The issue has been volatile in today's session following the announcement that the FDA has granted accelerated approval for Ocalivia for the treatment of patients with PBC.
After a quick sprint on very little volume in the pre-market session to $169.77, investors had the opportunity to purchase shares off the open, just below Friday's low ($137.85), reaching $137.11 before turning higher. The ensuing rally has taken the issue to $150.95 before retreating to its current level.
The current high coincides with a pair of highs from May 2 ($151.06) and May 3 ($151.33).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
